相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3 and NPM1 Mutations in Myelodysplastic Syndromes Frequency and Potential Value for Predicting Progression to Acute Myeloid Leukemia
Ashish Bains et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Prognostic Value of FLT3 Mutations Among Different Cytogenetic Subgroups in Acute Myeloid Leukemia
Fabio P. S. Santos et al.
CANCER (2011)
Will newer tyrosine kinase inhibitors have an impact in AML?
Mark J. Levis
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia
Elizabeth A. Griffiths et al.
EPIGENETICS (2010)
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
Farhad Ravandi et al.
LEUKEMIA RESEARCH (2010)
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples
Zhuang Zuo et al.
MODERN PATHOLOGY (2009)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
Susan P. Whitman et al.
BLOOD (2008)
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia
Michela Palmisano et al.
HAEMATOLOGICA (2007)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Steven Knapper et al.
BLOOD (2006)
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
J. Cloos et al.
LEUKEMIA (2006)
Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations
M Griffiths et al.
LEUKEMIA (2005)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
T Suzuki et al.
BLOOD (2005)
Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type
WN Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
K Ozeki et al.
BLOOD (2004)
Heterogeneous patterns of FLT3 ASP835 mutations in relapsed de novo acute myeloid leukemia:: A comparative analysis of 120 paired diagnostic and relapse bone marrow samples
LY Shih et al.
CLINICAL CANCER RESEARCH (2004)
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia
S Schnittger et al.
ACTA HAEMATOLOGICA (2004)
Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy
J Tiesmeier et al.
LEUKEMIA RESEARCH (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
PD Kottaridis et al.
BLOOD (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
